Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details)

v3.22.1
Subsequent Events (Details) - Subsequent event - R-Bridge Financing - China
$ in Millions
Mar. 29, 2022
USD ($)
Subsequent Event  
Upfront payment $ 15.0
Milestone payment upon first commercial sale in China 15.0
Commercialization milestone payments $ 10.0
Jiangsu Nhwa Pharmaceutical Co Ltd  
Subsequent Event  
Net revenue interest in U.S. net sales (as a percent) 4.00%
Cap of U.S. revenue interest if Chinese approval occurs by year-end 2023 $ 10.0
Net revenue interest in U.S. net sales if approval target is not reached (as a percent) 7.00%
Milestone payment upon regulatory approval in China $ 3.0